All Comments by Takaomi Saido

  1. Enteric alpha-synuclein expression is increased in Parkinson's disease but not Alzheimer's disease.
  2. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
  3. Amyloid deposition, hypometabolism, and longitudinal cognitive decline.
  4. Generation of monoclonal antibody fragments binding the native γ-secretase complex for use in structural studies.
  5. α-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies.
  6. Opposing effects of aging on large-scale brain systems for memory encoding and cognitive control.
  7. Neuronal activity and secreted amyloid β lead to altered amyloid β precursor protein and presenilin 1 interactions.
  8. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults.
  9. Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue.
  10. Quetiapine modulates conditioned anxiety and alternation behavior in Alzheimer's transgenic mice.
  11. Biomarker Positive and Negative Subjects in the ADNI Cohort: Clinical Characterization.
  12. Impact of Angiotensin Receptor Blockers on Alzheimer Disease Neuropathology in a Large Brain Autopsy Series.
  13. Activity dependent degeneration explains hub vulnerability in Alzheimer's disease.
  14. Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease.
  15. Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation.